Literature DB >> 22645090

Importance of liver biopsy findings in immunosuppression management: biopsy monitoring and working criteria for patients with operational tolerance.

.   

Abstract

Obstacles to morbidity-free long-term survival after liver transplantation (LT) include complications of immunosuppression (IS), recurrence of the original disease and malignancies, and unexplained chronic hepatitis and graft fibrosis. Many programs attempt to minimize chronic exposure to IS by reducing dosages and stopping steroids. A few programs have successfully weaned a highly select group of recipients from all IS without apparent adverse consequences, but long-term follow-up is limited. Patients subjected to adjustments in IS are usually followed by serial liver chemistry tests, which are relatively insensitive methods for detecting allograft damage. Protocol biopsy has largely been abandoned for hepatitis C virus-negative recipients, at least in part because of the inability to integrate routine histopathological findings into a rational clinical management algorithm. Recognizing a need to more precisely categorize and determine the clinical significance of findings in long-term biopsy samples, the Banff Working Group on Liver Allograft Pathology has reviewed the literature, pooled the experience of its members, and proposed working definitions for biopsy changes that (1) are conducive to lowering IS and are compatible with operational tolerance (OT) and (2) raise concern for closer follow-up and perhaps increased IS during or after IS weaning. The establishment of guidelines should help us to standardize analyses of the effects of various treatments and/or weaning protocols and more rigorously categorize patients who are assumed to show OT. Long-term follow-up using standardized criteria will help us to determine the consequences of lowering IS and to define and determine the incidence and robustness of OT in liver allografts.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22645090     DOI: 10.1002/lt.23481

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  21 in total

Review 1.  Enhancing the Value of Histopathological Assessment of Allograft Biopsy Monitoring.

Authors:  Michelle A Wood-Trageser; Andrew J Lesniak; Anthony J Demetris
Journal:  Transplantation       Date:  2019-07       Impact factor: 4.939

Review 2.  ABO-compatible liver allograft antibody-mediated rejection: an update.

Authors:  Anthony J Demetris; Adriana Zeevi; Jacqueline G O'Leary
Journal:  Curr Opin Organ Transplant       Date:  2015-06       Impact factor: 2.640

3.  Immunosuppression Withdrawal in Liver Transplant Recipients on Sirolimus.

Authors:  Josh Levitsky; Bryna E Burrell; Sai Kanaparthi; Laurence A Turka; Sunil Kurian; Alberto Sanchez-Fueyo; Juan J Lozano; Anthony Demetris; Andrew Lesniak; Allan D Kirk; Linda Stempora; Guang-Yu Yang; James M Mathew
Journal:  Hepatology       Date:  2020-06-08       Impact factor: 17.425

4.  Evidence of Chronic Allograft Injury in Liver Biopsies From Long-term Pediatric Recipients of Liver Transplants.

Authors:  Sandy Feng; John C Bucuvalas; Anthony J Demetris; Bryna E Burrell; Katherine M Spain; Sai Kanaparthi; John C Magee; David Ikle; Andrew Lesniak; Juan J Lozano; Estella M Alonso; Robert A Bray; Nancy E Bridges; Edward Doo; Howard M Gebel; Nitika A Gupta; Ryan W Himes; Annette M Jackson; Steven J Lobritto; George V Mazariegos; Vicky L Ng; Elizabeth B Rand; Averell H Sherker; Shikha Sundaram; Yumirle P Turmelle; Alberto Sanchez-Fueyo
Journal:  Gastroenterology       Date:  2018-08-23       Impact factor: 22.682

Review 5.  Management of immunosuppressant agents following liver transplantation: Less is more.

Authors:  Mustafa S Ascha; Mona L Ascha; Ibrahim A Hanouneh
Journal:  World J Hepatol       Date:  2016-01-28

6.  Serum MicroRNA Transcriptomics and Acute Rejection or Recurrent Hepatitis C Virus in Human Liver Allograft Recipients: A Pilot Study.

Authors:  Thangamani Muthukumar; Kemal M Akat; Hua Yang; Joseph E Schwartz; Carol Li; Heejung Bang; Iddo Z Ben-Dov; John R Lee; David Ikle; Anthony J Demetris; Thomas Tuschl; Manikkam Suthanthiran
Journal:  Transplantation       Date:  2022-04-01       Impact factor: 4.939

7.  Improvements in Disease-Specific Health-Related Quality of Life of Pediatric Liver Transplant Recipients During Immunosuppression Withdrawal.

Authors:  Saeed Mohammad; Shikha S Sundaram; Kristen Mason; Steven Lobritto; Mercedes Martinez; Yumirle P Turmelle; John Bucuvalas; Sandy Feng; Estella M Alonso
Journal:  Liver Transpl       Date:  2021-05       Impact factor: 5.799

8.  Immunosuppression status of liver transplant recipients with hepatitis C affects biopsy-proven acute rejection.

Authors:  Jong Man Kim; Kwang-Woong Lee; Gi-Won Song; Bo-Hyun Jung; Hae Won Lee; Nam-Joon Yi; ChoonHyuck David Kwon; Shin Hwang; Kyung-Suk Suh; Jae-Won Joh; Suk-Koo Lee; Sung-Gyu Lee
Journal:  Clin Mol Hepatol       Date:  2016-09-25

9.  Increased survival in hepatitis c patients who underwent living donor liver transplant: a case-control study with propensity score matching.

Authors:  Jong Man Kim; Kwang-Woong Lee; Gi-Won Song; Bo-Hyun Jung; Hae Won Lee; Nam-Joon Yi; Choon Hyuck David Kwon; Shin Hwang; Kyung-Suk Suh; Jae-Won Joh; Suk-Koo Lee; Sung-Gyu Lee
Journal:  Ann Surg Treat Res       Date:  2017-12-01       Impact factor: 1.859

10.  Outcomes for patients with HCV after liver transplantation in Korea: a multicenter study.

Authors:  Jong Man Kim; Kwang-Woong Lee; Gi-Won Song; Bo-Hyun Jung; Hae Won Lee; Nam-Joon Yi; Choon Hyuck David Kwon; Shin Hwang; Kyung-Suk Suh; Jae-Won Joh; Suk-Koo Lee; Sung-Gyu Lee
Journal:  Ann Surg Treat Res       Date:  2015-12-29       Impact factor: 1.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.